Empirical therapy of community-acquired pneumonia: Macrolides are not ideal choices

Research output: Contribution to journalReview articlepeer-review

Abstract

Macrolides are a rational option for patients with community-acquired pneumonia managed as outpatients. For hospitalized patients, they may be used to supplement other drugs, usually betalactams, because of their excellent activity versus Legionella, Chlamydia pneumoniae, and Mycoplasma pneumoniae. The reason for lack of confidence for macrolides as single agents in hospitalized patients, especially for seriously ill patients, is the lack of studies confirming good results for seriously ill patients, and relatively poor in vitro activity against some important pathogens. Resistance is noted to erythromycin, clarithromycin, and azithromycin by 10% to 15% of Streptococcus pneumoniae, about 40% of penicillin resistant S pneumoniae, most Fusobacteria, some Streptococcus aureus, and all gram-negative bacilli.

Original languageEnglish (US)
Pages (from-to)329-333
Number of pages5
JournalSeminars in Respiratory Infections
Volume12
Issue number4
StatePublished - Dec 1 1997

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Microbiology (medical)

Fingerprint

Dive into the research topics of 'Empirical therapy of community-acquired pneumonia: Macrolides are not ideal choices'. Together they form a unique fingerprint.

Cite this